Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: Prevalence and survival - An analysis of data from the ERA-EDTA Registry

Nephrology Dialysis Transplantation

Volumn 29, Issue , 2014, Pages iv15-iv25

  Spithoven, Edwin M ^a   Kramer, Anneke ^b   Meijer, Esther ^a   Orskov, Bjarne ^c   Wanner, Christoph ^d   Abad, Jose M ^e   Aresté, Nuria ^f   De La Torre, Ramón Alonso ^g   Caskey, Fergus ^h   Couchoud, Cécile ⁱ   Finne, Patrik ^j   Heaf, James ^k   Hoitsma, Andries ^l   De Meester, Johan ^m   Pascual, Julio ⁿ   Postorino, Maurizio ^o   Ravani, Pietro ^p   Zurriaga, Oscar ^q,r   Jager, Kitty J ^b   Gansevoort, Ron T ^a,aa   De Los Angeles Garcia Bazaga M ^s   Metcalfe, W ^t   Rodrigo, E ^u   Quiros J R ^v   Budde, K ^w   Chauveau, D ^w,x   Devuyst, O ^x,y   Ecder, T ^z   Eckardt, K U ^aa   Kottgen A ^ab   Ong, A C ^ab,ac   Petzold, K ^x   Pirson, Y ^ad   Remuzzi, G ^ae   Torra, R ^af   Sandford, R N ^ag   Serra, A L ^ac   Tesar, V ^ah   Walz, G ^a   Wuthrich R P ^ac   Antignac, C ^ai,aj   Bindels, R ^ak   Emma, F ^al   Maxwell, P H ^ag   Ronco, P ^am   Schaefer, F ^an   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g Public Health Dirct   (Spain)

^h Richard Bright Renal Unit   (United Kingdom)

ⁱ AGENCE DE LA BIOMÉDECINE   (France)

^j Finnish Registry for Kidney Diseases   (Finland)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m AZ Nikolaas   (Belgium)

ⁿ HOSPITAL DEL MAR   (Spain)

^o CNR Consiglio Nazionale delle Ricerche   (Italy)

^p UNIVERSITY OF CALGARY   (Canada)

^q Generalitat Valenciana   (Spain)

^r CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^s Extremadura Renal Registry   (Spain)

^t ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^u HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^v Principado de Asturias   (Spain)

^w CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^x CHU RANGUEIL   (France)

^y UNIVERSITY OF ZURICH   (Switzerland)

^z ISTANBUL UNIVERSITY   (Turkey)

^aa UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ab UNIVERSITY OF FREIBURG   (Germany)

^ac UNIVERSITY OF SHEFFIELD   (United Kingdom)

^ad UCL   (Belgium)

^ae MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^af UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^ag UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ah CHARLES UNIVERSITY   (Czech Republic)

^ai HÔPITAL NECKER ENFANTS MALADES   (France)

^aj IMAGINE INSTITUTE   (France)

^ak RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^al BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^am SORBONNE UNIVERSITÉ   (France)

^an UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

ADPKD; Epidemiology; Prevalence; Renal replacement therapy; Survival

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRIA; BELGIUM; CAUSE OF DEATH; CONTROLLED STUDY; DENMARK; FEMALE; FINLAND; FRANCE; GREECE; HEMODIALYSIS; HUMAN; INCIDENCE; ITALY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; ROMANIA; SPAIN; SURVIVAL ANALYSIS; SWEDEN; UNITED KINGDOM; ADPKD; EPIDEMIOLOGY; EUROPE; MIDDLE AGED; REGISTER; STATISTICS; SURVIVAL; SURVIVAL RATE; TIME;

ADPKD; EPIDEMIOLOGY; PREVALENCE; RENAL REPLACEMENT THERAPY; SURVIVAL;

AGED; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREVALENCE; REGISTRIES; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 84910156639     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu017     Document Type: Article

References (46)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301
2. Hateboer N, v Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353: 103-107
3. Iglesias CG, Torres VE, Offord KP et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis 1983; 2: 630-639
4. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332-342
5. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485
6. Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58: 925-943
7. Del Peso G, Bajo MA, Costero O et al. Risk factors for abdominal wall complications in peritoneal dialysis patients. Perit Dial Int 2003; 23: 249-254
8. Hadimeri H, Johansson AC, Haraldsson B et al. CAPD in patients with autosomal dominant polycystic kidney disease. Perit Dial Int 1998; 18: 429-432
9. Kumar S, Fan SL, Raftery MJ et al. Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int 2008; 74: 946-951
10. Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002; 57: 208-214
11. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777-784
12. Roscoe JM, Brissenden JE, Williams EA et al. Autosomal dominant polycystic kidney disease in Toronto. Kidney Int 1993; 44: 1101-1108
13. Haynes R, Kheradmand F,Winearls CG. Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study. Nephron Clin Pract 2012; 120: c42-c47
14. Orskov B, Romming Sorensen V, Feldt-Rasmussen B et al. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010; 5: 2034-2039
15. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63: 678-685
16. van Dijk PC, Jager KJ, de Charro F et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16: 1120-1129
17. Stel VS, Kramer A, Zoccali C et al. The 2006 ERA-EDTA Registry annual report: a précis. J Nephrol 2009; 22: 1-12
18. Haller M, Gutjahr G, Kramar R et al. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011; 26: 2988-2995
19. Cleemput I, Beguin C, de la Kethule Y et al. Organisation et financement de la dialyse chronique en Belgique. KCE Reports 124B: vii. Heath Technology Assessment (HTA). Bruxelles Centre federal d'expertise des soins de sante (KCE), 2010
20. Maschoreck TR, Sorensen MC, Andresen M et al. Cost analysis of dialysis treatment at the Odense University Hospital and the Sonderborg Hospital. Ugeskr Laeger 1998; 160: 7418-7424
21. Salonen T, Reina T, Oksa H et al. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis 2003; 42: 1228-1238
22. Blotiere PO, Tuppin P, Weill A et al. The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation. Nephrol Ther 2010; 6: 240-247
23. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 2008; 86: 85-96
24. Tediosi F, Bertolini G, Parazzini F et al. Cost analysis of dialysis modalities in Italy. Health Serv Manage Res 2001; 14: 9-17
25. Neil N, Walker DR, Sesso R et al. Gaining efficiencies: resources and demand for dialysis around the globe. Value Health 2009; 12: 73-79
26. Villa G, Rodriguez-Carmona A, Fernandez-Ortiz L et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol Dial Transplant 2011; 26: 3709-3714
27. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis - a cost-utility analysis. Perit Dial Int 2002; 22: 39-47
28. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44: 215-232
29. Baboolal K, McEwan P, Sondhi S et al. The cost of renal dialysis in a UK setting - a multicentre study. Nephrol Dial Transplant 2008; 23: 1982-1989
30. Spithoven EM, Kramer A, Meijer E et al. Analysis of data from the ERAEDTA registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int 2014; doi: 10.1038/ki.2014.120
31. Davies F, Coles GA, Harper PS et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991; 79: 477-485
32. Neumann HP, Jilg C, Bacher J et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant 2013; 28: 1472-1487
33. Simon P, Le Goff JY, Ang KS et al. [Epidemiologic data, clinical and prognostic features of autosomal dominant polycystic kidney disease in a French region]. Nephrologie 1996; 17: 123-130
34. de Almeida E, Sousa A, Pires C et al. Prevalence of autosomal-dominant polycystic kidney disease in Alentejo, Portugal. Kidney Int 2001; 59: 2374
35. Caskey FJ, Kramer A, Elliott RF et al. Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 2011; 26: 2604-2610
36. Covic A, Schiller A. Burden of disease - prevalence and incidence of ESRD in selected European regions and populations. Clin Nephrol 2010; 74 (Suppl 1): S23-S27
37. Goffin E, Pirson Y. Is peritoneal dialysis a suitable renal replacement therapy in autosomal dominant polycystic kidney disease? Nat Clin Pract Nephrol 2009; 5: 122-123
38. Hou W, Lv J, Perkovic V et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013; 34: 1807-1817
39. Baker WL, Coleman CI, Kluger J et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151: 861-871
40. Patch C, Charlton J, Roderick PJ et al. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011; 57: 856-862
41. Wiviott SD, White HD, Ohman EM et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013; 382: 605-613
42. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl JMed 2012; 367: 2407-2418
43. Caroli A, Perico N, Perna A et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013; 382: 1485-1495
44. Meijer E, Drenth JP, d'Agnolo H et al. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2013; doi:10.1053/j.ajkd.2013.10.011
45. Jardine MJ, Liyanage T, Buxton E et al. mTOR inhibition in autosomaldominant polycystic kidney disease (ADPKD): the question remains open. Nephrol Dial Transplant 2013; 28: 242-244
46. Stallone G, Infante B, Grandaliano G et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant 2012; 27: 3560-3567